Arovella has moved its off-the-shelf CAR-iNKT therapy ALA-101 into human testing, dosing the first patient in the phase 1 SAPPHIRE trial. The study will now test safety and early signs of activity, with initial data expected in early 2027.
- First patient dosed at The Alfred in phase 1 SAPPHIRE trial
- ALA-101 targets relapsed or refractory CD19-positive blood cancers
- Open-label study will assess safety, pharmacology and preliminary efficacy
- Adaptive dose escalation and expansion design
- Initial trial data expected in early 2027
ALA-101 reaches first-in-human dosing
Arovella Therapeutics Ltd (ASX:ALA) has crossed the most important near-term threshold for its lead therapy: a patient has received ALA-101 for the first time. The dose was administered at The Alfred under the supervision of Dr Salvatore Fiorenza, beginning the company’s phase 1 SAPPHIRE trial in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma and leukaemia.
The milestone turns a programme that had been moving through manufacturing and site preparation into an active clinical study. Arovella had previously reported the release of two ALA-101 clinical batches and the activation of trial sites ahead of first dosing, while the latest announcement confirms that treatment has now begun.
Trial will test safety before efficacy
SAPPHIRE is an open-label, multi-centre dose-escalation and expansion study. Its initial phase will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of a single ALA-101 dose. Patients receive lymphodepleting chemotherapy before the cell therapy, and dosing will be staggered to allow safety reviews between participants.
The study uses a backfill Bayesian Optimal Interval design, allowing enrolment to expand at dose levels only after they have been reviewed and considered acceptable from a safety perspective. That structure is intended to help Arovella identify a dose suitable for a potential phase 2 study while allowing additional exploration in disease subtypes where early clinical activity emerges. The announcement provides no safety or efficacy results yet.
Off-the-shelf platform faces its first clinical test
ALA-101 is an allogeneic CD19 CAR-iNKT therapy made from healthy donor-derived cells. Arovella says the approach is designed to be manufactured in advance and supplied when needed, contrasting with autologous CAR-T treatments that use a patient’s own cells. The company’s broader platform is licensed from Imperial College London and is also intended to support programmes in solid tumours and autoimmune disease.
Initial SAPPHIRE data are expected in early calendar 2027. The key question will not simply be whether ALA-101 can be administered, but whether the trial produces a sufficiently clear balance of safety, cell expansion, persistence, B-cell depletion and preliminary activity to justify selecting a phase 2 dose.
Bottom Line?
The first dose removes a major development hurdle, but the investment case now depends on recruitment, dose-escalation safety reviews and the quality of early 2027 data.
Questions in the middle?
- How quickly will Arovella enrol patients across the dose-escalation and expansion portions of SAPPHIRE?
- Will ALA-101 show durable expansion, persistence and B-cell depletion at tolerable doses?
- Can early clinical signals support a phase 2 programme and broader use of the CAR-iNKT platform?